Extended Prophylaxis With Bemiparin for the Prevention Of Late Venous Thromboembolism After Abdominal or Pelvic Surgery for Cancer: A Double-Blind, Randomised, Placebo-Controlled Trial
Vijay V Kakkar, Jose L Balibrea, Javier Martinez-González, Paolo Prandoni on behalf of the CANBESURE Study Investigators
A Predictive Model for Scoring Venous Thromboembolism Risk Factors in Hospitalized Medical Patients: Findings from the IMPROVE Registry
Alex C. Spyropoulos, F. Anderson, G. FitzGerald H Decousus, and V. Tapson, for the IMPROVE Investigators
Multiple SNP Testing to predict risk of First Venous Thrombosis
ID Bezemer, CJM Doggen, S le Cessie, PH Reitsma, LA Bare, FR Rosendaal
Appropriate VTE Prophylaxis, Compared with Partial VTE Prophylaxis, Leads to Lower VTE Recurrence and Cost in US Medical Patients
A. N. Amin, M. Hussein, D. Battleman, J. Lin, S. Stemkowski, and G. J. Merli
Prevalence of Venous Thromboembolism in the USA: Now and the Future
S Deitelzweig, J Lin, BH Johnson, KL Schulman
Are Hospitals Following Guidelines for VTE Prevention? the Veneous Thromoembolism Study to Assess the Rate of Thromboprophylaxis
Alpesh Amin MD, MBA, FACP
Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
Aneel A. Ashrani MD, BS, MSc
Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years
Ola E. Dahl, MD, MDsc
Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty
Takashi Fuji, MD
Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors
Uma Sinha, PhD
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding
Alexander GG Turpie, MD
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4
Alexander GG Turpie, MD
Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study
Alexander GG Turpie, MD
Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I
Eriksson BI, Dahl OE, Ahnfelt L, et al.
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee Replacement: The BISTRO II Randomized Trial
Eriksson BI, Dahl OE, Buller HR, et al.
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism Following Major Orthopedic Surgery
Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson B
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism Following Major Orthopedic Surgery
Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson B
Dabigatran Etexilate Versus Enoxaparin in Preventing Venous Thromboembolism Following Total Knee Arthroplasty
Friedman RJ, Caprini JA, Comp PC, et al.
Late Breaking Clinical Trial - A Dose Finding Study Of The Oral Direct Factor Xa Inhibitor Apixaban in the Treatment of Patients with Acute Symptomatic Deep Vein Thrombosis: The Botticelli Investigators
Buller HR
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Patients After Total Knee Replacement: A Phase II Dose-Ranging Study
Turpie AG, Fisher WD, Bauer KA, et al.
Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement
Eriksson BI, Borris L, Dahl OE, et al.
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery – Results of the RECORD 3 Study
Lassen MR,Turpie AG,Rosencher N, et al.
Treatment of Proximal Deep Vein Thrombosis (DVT): Rivaroxaban Once or Twice Daily Had Similar Efficacy and Safety to Standard Therapy in Phase II Studies
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement (THR)
Eriksson BI,Misselwitz F,Mueck F, et al.
Dabigatran Etexilate Is Effective And Safe For The Extended Prevention Of Venous Thromboembolism Following Total Hip Replacement
BI Eriksson, OE Dahl, N Rosencher, et al.